多索茶碱治疗替格瑞洛相关呼吸困难的安全性和有效性分析

发布时间：2018-10-31 15:18

【摘要】：目的:探讨冠心病患者应用多索茶碱治疗替格瑞洛相关呼吸困难的安全性及有效性。方法:选取2015-02至2016-07期间在郑州大学第一附属医院心内科服用替格瑞洛后出现相关呼吸困难的冠心病患者172例,随机分为干预组(n=86)及对照组(n=86)。干预组给予多索茶碱片(商品名:安赛玛,规格:200 mg/片)早晚各1片,服用5天;对照组给予安慰剂。记录两组1天后呼吸困难总缓解率,治疗前、后血小板聚集率以及6个月心原性死亡、心肌梗死、卒中、出血等心血管不良事件的发生率。结果:应用多索茶碱1天后,干预组呼吸困难缓解率明显高于对照组(93%vs 63%,P0.05);服用多索茶碱前、后,两组血小板聚集率差异均无统计学意义(P0.05);两组心血管不良事件的发生率无差异(P0.05)。结论:多索茶碱治疗替格瑞洛相关呼吸困难有效,并且不影响替格瑞洛抗血小板聚集作用。
[Abstract]:Objective: to investigate the safety and efficacy of doxophylline in the treatment of tigrilo-associated dyspnea in patients with coronary heart disease. Methods: 172 patients with coronary heart disease associated with dyspnea were randomly divided into intervention group (n = 86) and control group (n = 86) during 2015-02 to 2016-07 in Department of Cardiology, first affiliated Hospital of Zhengzhou University. The intervention group received doxofylline tablets (trade name: Ansama, specification: 200 mg/ tablets) 1 tablet in the morning and evening for 5 days, while the control group was given placebo. The total remission rate of dyspnea, the platelet aggregation rate before and after treatment and the incidence of cardiovascular adverse events such as cardiac death, myocardial infarction, stroke and hemorrhage were recorded in both groups. Results: the remission rate of dyspnea in the intervention group was significantly higher than that in the control group (P 0.05), but there was no significant difference in platelet aggregation rate between the two groups before and after the administration of doxofylline (P0.05). There was no difference in the incidence of cardiovascular adverse events between the two groups (P0.05). Conclusion: doxofylline is effective in the treatment of tigrilo-associated dyspnea and does not affect the antiplatelet aggregation of tigrilol.
【作者单位】：郑州大学第一附属医院心内科;
【分类号】：R541.4

【相似文献】